Treatment with mogamulizumab or lenalidomide for relapsed adult T‐cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience
- 10 January 2020
- journal article
- research article
- Published by Wiley in Hematological Oncology
- Vol. 38 (2) , 162-170
Abstract
Mogamulizumab (Mog) and lenalidomide (Len) are new therapeutic candidates for relapsed adult T‐cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation (allo‐HSCT). In the present study, we retrospectively analyzed 12 patients who received Mog or Len monotherapy for relapsed ATL after allo‐HSCT. Eight and three patients received Mog and Len, respectively. The remaining patient received Mog for the first relapse and Len for the third relapse. A complete response was achieved by three and two patients who received Mog and Len, respectively, two and one of whom remained alive with a complete response for more than 20 months. In terms of adverse events, the emergence or progression of graft‐versus‐host disease was observed in three out of four patients treated with Len and in none of the patients treated with Mog. The development or progression of cytomegalovirus reactivation was detected in four out of eight patients treated with Mog and in none of those treated with Len. The present results suggest that Mog and Len would be promising treatment options for relapsed ATL after allo‐HSCT and need to be selected based on adverse event profiles.Keywords
This publication has 55 references indexed in Scilit:
- Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experienceBlood, 2013
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trialHaematologica, 2012
- Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patientsBone Marrow Transplantation, 2012
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statementLeukemia, 2011
- Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in miceJournal of Clinical Investigation, 2010
- Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trialsBone Marrow Transplantation, 2010
- Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus MeetingJournal of Clinical Oncology, 2009
- Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphomaLeukemia, 2005
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaProceedings of the National Academy of Sciences, 1980